Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine

Trial Profile

The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs AVL 3288 (Primary) ; Nicotine
  • Indications Cognition disorders
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 11 Apr 2018 Status changed from not yet recruiting to withdrawn prior to enrolment as drug supplier did not come through.
    • 16 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top